SEC Comment Letter for ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309) (ORMP) — Feb 4, 2020
ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309)
Date: Feb. 4, 2020 · CIK: 0001176309 · Accession: 0000000000-20-001091
AI Filing Summary & Sentiment
File numbers found in text: 333-236194
Letter
February 4, 2020 Nadav Kidron President and Chief Executive Officer Oramed Pharmaceuticals Inc. 1185 Avenue of the Americas, Suite 228 New York, New York 10036 Re:Oramed Pharmaceuticals Inc. Registration Statement on Form S-3 Filed January 31, 2020 File No. 333-236194 Dear Mr. Kidron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Oded Har-Even
Show Raw Text
February 4, 2020
Nadav Kidron
President and Chief Executive Officer
Oramed Pharmaceuticals Inc.
1185 Avenue of the Americas, Suite 228
New York, New York 10036
Re:Oramed Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed January 31, 2020
File No. 333-236194
Dear Mr. Kidron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Oded Har-Even